Rubicon Research credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
259259
−86.6−86.6
0.20×0.20×
−0.07×−0.07×
0.65×0.65×
−0.19×−0.22×
8.42×8.42×
16.8%16.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

RUBICON₹1,559.30

Rubicon Research Ltd.

· Pharma & Health
₹ CrorePeersSHILPAMEDSPARCSTARSUPRIYAPARKHOSPSTHYROCAREMETROPOLISMARKSANSMcap ₹25,742 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt259.4259.4
Net Debt-86.6-86.6
Total Debt/Equity0.200.20
Net Debt/Equity-0.07-0.07
Total Debt/EBITDA0.650.65
Net Debt/EBITDA-0.22-0.19
Interest Coverage (EBIT/Interest)8.428.42
Total Debt/Total Capital %16.7516.75
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.